Jose L. Lopez-Ribot to Amphotericin B
                            
                            
                                This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Amphotericin B.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            1.127
         
        
        
     
 
    
        
        - 
            Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother. 2011 Jul; 55(7):3591-3.
            
            
                Score: 0.392
             
- 
            Ramage G, VandeWalle K, Bachmann SP, Wickes BL, L?pez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother. 2002 Nov; 46(11):3634-6.
            
            
                Score: 0.218
             
- 
            Ramage G, Vande Walle K, Wickes BL, L?pez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001 Sep; 45(9):2475-9.
            
            
                Score: 0.201
             
- 
            Redding S, Bhatt B, Rawls HR, Siegel G, Scott K, Lopez-Ribot J. Inhibition of Candida albicans biofilm formation on denture material. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 May; 107(5):669-72.
            
            
                Score: 0.086
             
- 
            Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, L?pez-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother. 2003 Nov; 47(11):3657-9.
            
            
                Score: 0.058
             
- 
            Srinivasan A, Gupta CM, Agrawal CM, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. Drug susceptibility of matrix-encapsulated Candida albicans nano-biofilms. Biotechnol Bioeng. 2014 Feb; 111(2):418-24.
            
            
                Score: 0.029
             
- 
            Siles SA, Srinivasan A, Pierce CG, Lopez-Ribot JL, Ramasubramanian AK. High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother. 2013 Aug; 57(8):3681-7.
            
            
                Score: 0.028
             
- 
            Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses. 2012 Jan; 55(1):80-5.
            
            
                Score: 0.025
             
- 
            Srinivasan A, Uppuluri P, Lopez-Ribot J, Ramasubramanian AK. Development of a high-throughput Candida albicans biofilm chip. PLoS One. 2011 Apr 22; 6(4):e19036.
            
            
                Score: 0.025
             
- 
            Ramage G, Tomsett K, Wickes BL, L?pez-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jul; 98(1):53-9.
            
            
                Score: 0.015
             
- 
            Ramage G, VandeWalle K, L?pez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett. 2002 Aug 27; 214(1):95-100.
            
            
                Score: 0.013
             
- 
            Viudes A, Pem?n J, Cant?n E, Salavert M, Ubeda P, L?pez-Ribot JL, Gobernado M. Two cases of fungemia due to Candida lusitaniae and a literature review. Eur J Clin Microbiol Infect Dis. 2002 Apr; 21(4):294-9.
            
            
                Score: 0.013
             
- 
            Viudes A, Cant?n E, Pem?n J, L?pez-Ribot JL, Gobernado M. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis]. Rev Esp Quimioter. 2002 Mar; 15(1):32-42.
            
            
                Score: 0.013
             
- 
            Kirkpatrick WR, Revankar SG, Mcatee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu RA, Rinaldi MG, Patterson TF. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol. 1998 Oct; 36(10):3007-12.
            
            
                Score: 0.010